Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

Alzheimer’s Markers Seen Way Before Symptoms

Dementia TodayPublished July 14, 20125 min read

Key points

  • Beta amyloid protein measurements may begin to show abnormalities more than 2 decades before overt symptoms of Alzheimer’s disease appear, researchers said.
  • “Our findings indicate the Alzheimer’s disease process begins more than 20 years before the clinical onset of dementia,” Bateman and colleagues concluded.
  • In the current study, Bateman and colleagues analyzed data on 128 DIAN participants, including 88 who carried the Alzheimer-associated mutations in the PSEN1, PSEN2, and/or APP genes.
  • They are also operating under an assumption that the trajectory of biomarkers and symptoms in autosomal dominant Alzheimer’s disease is similar to that in sporadic, late-onset forms, except that it begins at a younger age.

Beta amyloid protein measurements may begin to show abnormalities more than 2 decades before overt symptoms of Alzheimer’s disease appear, researchers said.

Imaging and cerebrospinal fluid (CSF) analyses of patients with a powerful genetic predisposition to Alzheimer’s disease showed that AB42 (a form of beta amyloid protein with 42 amino acids) levels began to decline about 25 years before expected symptom onset, according to Randall Bateman, MD, of Washington University in St. Louis, and colleagues.

In addition, beta amyloid plaques could be imaged in patients’ brains some 15 years before expected symptom onset, the researchers reported online in the New England Journal of Medicine.

“Our findings indicate the Alzheimer’s disease process begins more than 20 years before the clinical onset of dementia,” Bateman and colleagues concluded.

The results were some of the first major data to be reported from a project called DIAN, the Dominantly Inherited Alzheimer Network. This is a prospective cohort study involving a projected 400 asymptomatic individuals whose family history suggests they may carry genetic mutations associated with autosomal dominant Alzheimer’s disease, an early-onset form of the condition.

In the current study, Bateman and colleagues analyzed data on 128 DIAN participants, including 88 who carried the Alzheimer-associated mutations in the PSEN1, PSEN2, and/or APP genes. The 40 noncarriers served as a control group for comparison. About one-quarter of carriers and noncarriers alike were positive for the epsilon-4 variant of APOE.

Although at this point the data are cross-sectional rather than longitudinal, the idea is that findings in DIAN mutation carriers prior to symptom onset may also apply to more common forms of the disease. The snapshots of individual participants, who are at different stages of the pre-symptomatic phase, can be assembled into a picture of the disease course over time, the researchers believe.

They are also operating under an assumption that the trajectory of biomarkers and symptoms in autosomal dominant Alzheimer’s disease is similar to that in sporadic, late-onset forms, except that it begins at a younger age.

The primary evaluations carried out in the study were measurements of AB42, AB40 (a 40-residue version of beta amyloid), and tau protein in CSF and brain scans using positron emission tomography and the Pittsburgh Compound B beta amyloid tracer. The latter allows detection and quantification of amyloid plaques in the brain.

Symptoms were evaluated with the Clinical Dementia Rating-Sum of Boxes, scored from 0 (normal cognition) to 18 (total impairment).

DIAN participants’ mean age at the evaluations was 39. Among the 88 mutation carriers, half were already symptomatic.

Noncarriers were largely free of amyloid plaques, according to the PET results. Plaques were detectable in the precuneus in participants estimated to be 15 years away from symptom onset, with the plaque volume increasing with the approach of projected symptom onset.

The CSF analyses indicated that levels of tau protein were increased in carriers 15 years before expected symptom onset, relative to noncarriers of similar age. At 10 years from expected symptom onset, AB42 in CSF began to be significantly lower in carriers. Plasma AB42 was increased in carriers relative to noncarriers at 15 years from expected symptom onset.

Bateman and colleagues developed a combined model incorporating the imaging, biochemical, and clinical data. It indicated that the decline in CSF AB42 levels in mutation carriers relative to noncarriers began 25 years before expected symptom onset.

Clinical signs of cognitive impairment were noticeable 10 years out, and global cognitive impairment was evident 5 years before.

Neurologists and other Alzheimer’s disease experts contacted by MedPage Today and ABC News agreed that the study findings were important, but many said the study fell short of “landmark” status because of the methodology.

Murali Doraiswamy, MD, of Duke University, was among the more enthusiastic commentators. “The DIAN study is poised to become the road map for all Alzheimer’s disease diagnostic and treatment studies over the next 10 years,” he said in an email.

But, he continued, “longitudinal DIAN findings will need to confirm what is being reported here. One also has to bear in mind that there are more than 200 different mutations known to cause familial Alzheimer’s disease and that there is likely significant heterogeneity within DIAN families that is yet to be teased out.”

Ronald Petersen, MD, of the Mayo Clinic in Rochester, Minn., was more skeptical. “Very interesting data but more useful for hypothesis generation than having direct implications at present,” he said in an email.

He added, “This may be an unusual form of the Alzheimer’s disease process and not generalizable to the disease as it exists in the community.”

The National Institute on Aging funded the study.

Study authors reported relationships with C2N Diagnostics, Merck, Novartis, Lilly, Genentech, AstraZeneca, Pfizer, Bayer, Bristol-Myers Squibb, Eisai, Janssen, and Avid. One co-author holds an intellectual property interest in the amyloid plaque imaging agent used in the study.

Primary source: New England Journal of Medicine
Source reference: Bateman R, et al “Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012; DOI:10.1056/NEJMoa202753.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.